Vivtex strives to transform drug development using a new platform technology called gastrointestinal tract organ robotic interface system (GI-ORIS™) that enables robotic screening with fully intact and functional organs. GI-ORIS™ technology was developed in the Langer lab at MIT and can be used for various applications (e.g. oral delivery of biologics, drug toxicity mitigation, spatial and temporal drug delivery). Vivtex leverages these unique capabilities of the GI-ORIS™ to develop new oral therapeutics. Vivtex's mission is to serve patients by increasing the efficacy, safety and adherence of existing and novel therapies. The company is in preclinical stage and has multiple drug development programs including reformulations of existing drugs as well as new chemical entities. The company was co-founded by Professor Robert Langer (MIT), Dr. Giovanni Traverso (Harvard Medical School), Doug Eby (Cambridge Science), and Thomas von Erlach.
Company Details
- Employees
- 18
- Founded
- -
- Address
- 135 William T Morrissey Blvd,
- in****@****tex.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- vivtex.com
- Keywords
- Manager jobs.
- HQ
- Boston, Massachusetts
Vivtex Questions
Vivtex's website is vivtex.com
Vivtex's LinkedIn profile is https://www.linkedin.com/company/vivtex
Vivtex has
18 employees.
View email and phone details for 18
employees at Vivtex.
Vivtex's industry is
Biotechnology Research
Vivtex's top competitors are
Portal,
Kytopen,
1910 Genetics,
Nona Biosciences,
Marengo Therapeutics,
Manifold Bio,
Spear Bio,
Incendia Therapeutics,
Qld Biotherapeutics Inc,
Pledge Therapeutics.
Vivtex's support email address is info@vivtex.com
Vivtex's categories are Biotechnology Research
Vivtex's founding year is 2018
